Rush University Medical Center 3rd Midwest Cellular Conference Treatment Options for Advanced Hematologic Malignancies 2024
$20.00
This Product is shared via google drive download link, So please share your correct Gmail id while placing the order .Please note that there are no CME points or certificate associated with this course Samples for Courses Can be found here : Free Samples Here!
Include: 16 videos, size: 4.5 GB
Rush University Medical Center 3rd Midwest Cellular Conference Treatment Options for Advanced Hematologic Malignancies 2024
Include: 16 videos, size: 4.5 GB
Target Audience: hematologists, medical oncologists, pharmacists, fellows and residents
Information:
Treatment options for relapsed/refractory (advanced) hematologic malignancies have progressed rapidly in only the last decade. Development of revolutionary treatment options, including CAR T-cell therapy, novel immunotherapies, and novel chemotherapeutic agents has only accelerated since the first product targeting CD19 was developed in 2003. These developments provide excellent opportunities for patients, and with opportunities arrive challenges for clinicians in maintaining optimal approaches to care. To address the educational need the 3rd Midwest Therapy Cellular Conference: Treatment Options for Advanced Hematologic Malignancies is planned .
This program is designed to meet the educational needs of hematologists, medical oncologists, pharmacists, fellows and residents, APP’s, oncology nurses and other healthcare professionals committed to the field of cellular treatment options for advanced hematologic malignancies.
LEARNING OBJECTIVES
Following participation in this activity, learners will:
-
Discuss individualized treatment options for high-risk patients with plasma cell diseases (multiple myeloma (MM), amyloidosis), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL),non-Hodgkin Lymphoma (NHL), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and aplastic anemia (AA).
-
Include autologous or allogeneic HCT and/or CAR-T cell therapy in treatment plans for patients with various refractory (advanced) hematologic malignancies.
-
Manage potential complications resulting from autologous or allogeneic HCT and/or CAR-T cell therapy.
-
Utilize newer chemotherapeutic treatment options in conjunction with HCT and CAR-T cell therapy for patients with various refractory (advanced) hematologic malignancies.
Topics:
- Advancements in Richter’s Transformation- Novel Agents and Cellular Therapies.mp4
- Allo-HSCT Conditioning Regimens- Current Status and Future Directions.mp4
- BCMA & Beyond- Novel Targets for Immunotherapy in MM.mp4
- Bone Marrow Failure- The Importance of Mutational Testing.mp4
- CAR-T vs. Bispecific Antibodies in RR MM- Insights and Future Directions.mp4
- Cellular Therapy Strategies for Persistent Disease After Induction for B-ALL.mp4
- Challenges and Treatment Strategies in Advanced Stage Hodgkin Lymphoma.mp4
- High-Risk Myeloma- Updates in Defining and Managing.mp4
- Is Post-HSCT Maintenance the SOC for AML..mp4
- Management of Viral Infections Post-Transplant- CMV, EBV, and HHV-6.mp4
- Off the Shelf CARs for DLBCL- Myths and Facts.mp4
- Optimal Timing of CAR T-Cell Therapies in MCL- Cellular Therapy and Beyond.mp4
- Selection and Sequencing of Chronic GVHD Therapy.mp4
- The Role of SCT Amidst Emerging Therapies in the Treatment of AL Amyloidosis.mp4
- Transplant-Associated TMA- Challenges and Current Treatment Options.mp4
- What is New in AML- Risk Classification, Germline Mutations, and Targeted Therapies.mp4
Related products
